front – Lab DB

Boehringer Ingelheim eyes MASH as the next front for survodutide, a GLP-1/glucagon receptor dual agonist.

Lana Keisha Jun 14, 2026 0

For decades, metabolic dysfunction-associated steatohepatitis (MASH), the more severe inflammatory form of fatty liver disease, was a silent epidemic, often…

Boehringer Ingelheim eyes MASH as the next front for survodutide, a GLP-1/glucagon receptor dual agonist.

YOU MAY HAVE MISSED

Brain Tumors Induce Widespread disruption of Calvarial Bone and Alteration of Skull Marrow Immune Landscape.

Retatrutide Eases Sleep Apnea and Knee Arthritis in New Phase 3 Data, Extending Lilly’s Obesity Lead Over Novo

The Fabric of Reality: Decoding the Metaphysical and Linguistic Complexities of Space-Time in Modern Physics

Science News: Empowering Public Understanding of Science, Medicine, and Technology Since 1921